|
Marketing Authorisations
|
|
|
Huge risks for uncertain efficacy
|
|
|
|
|
|
|
|
Improvement in navigational ability in dim light, but questions remain over the risks
|
|
|
|
|
|
|
|
|
|
|
Too many uncertainties over its efficacy as well as its harms
|
|
|
|
|
|
|
|
|
|
|
No better than adalimumab, and with more limited follow-up
|
|
|
|
|
|
Colchicine no more effective than naproxen
|
|
|
|
|
|
|